The Southwest Oncology Group (SWOG) is very keen to complete the accrual of patients to a small, Phase II, pilot study of the use of abiraterone acetate (Zytiga) in the treatment of men with metastatic prostate cancer and a less than optimal response to standard androgen deprivation therapy (ADT). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, deprivation, response, sub-optimal | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site